In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Sciences Ltd.

Division of Roivant Sciences Inc.
www.axovant.com

Latest From Axovant Sciences Ltd.

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Why Novo Holdings Has Invested In ‘Hidden Gem’ Oxford Biomedica

Life sciences investor Novo Holdings buys 10% stake in UK gene therapy biotech.

Deals Companies

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Financing StartUps and SMEs

Urovant’s Vibegron Faces Tough Commercial Climb Despite Phase III Success

Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.

Gynecology & Urology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    David Nassif, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, Chief Business Officer
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, CMO
    Paul Korner, MD, SVP, Clin. Dev.
  • Contact Info
  • Axovant Sciences Ltd.
    Phone: 1-295-5950
    20-22 Bedford Row
    London, X0 WC1R 4J
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register